stoxline Quote Chart Rank Option Currency Glossary
  
LivaNova PLC (LIVN)
55.94  0.07 (0.13%)    03-28 16:00
Open: 55.86
High: 56.705
Volume: 373,548
  
Pre. Close: 55.87
Low: 55.86
Market Cap: 3,018(M)
Technical analysis
2024-03-28 4:52:41 PM
Short term     
Mid term     
Targets 6-month :  67.21 1-year :  78.51
Resists First :  57.54 Second :  67.21
Pivot price 53.52
Supports First :  52.69 Second :  49.69
MAs MA(5) :  55.31 MA(20) :  53.67
MA(100) :  50.29 MA(250) :  50.5
MACD MACD :  0.7 Signal :  0.5
%K %D K(14,3) :  76.2 D(3) :  71.8
RSI RSI(14): 58.9
52-week High :  59.86 Low :  42.16
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ LIVN ] has closed below upper band by 22.7%. Bollinger Bands are 39.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 56.8 - 57.07 57.07 - 57.32
Low: 55.18 - 55.5 55.5 - 55.79
Close: 55.42 - 55.94 55.94 - 56.41
Company Description

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

Headline News

Thu, 28 Mar 2024
LivaNova PLC (NASDAQ:LIVN) Stake Raised by SG Americas Securities LLC - Defense World

Thu, 28 Mar 2024
LivaNova PLC (NASDAQ:LIVN) Given Average Rating of “Hold” by Brokerages - Defense World

Thu, 28 Mar 2024
Analysts Set LivaNova PLC (NASDAQ:LIVN) Price Target at $64.40 - MarketBeat

Wed, 27 Mar 2024
LivaNova's (LIVN) Buy Rating Reaffirmed at Mizuho - MarketBeat

Thu, 21 Mar 2024
LivaNova to Announce First-Quarter 2024 Results - Business Wire

Wed, 20 Mar 2024
Should You Sell LivaNova PLC (LIVN) in Medical Devices Industry? - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 54 (M)
Shares Float 54 (M)
Held by Insiders 0.5 (%)
Held by Institutions 104.5 (%)
Shares Short 2,720 (K)
Shares Short P.Month 2,310 (K)
Stock Financials
EPS 0.31
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 23.7
Profit Margin 1.5 %
Operating Margin 6.8 %
Return on Assets (ttm) 1.7 %
Return on Equity (ttm) 1.4 %
Qtrly Rev. Growth 12.8 %
Gross Profit (p.s.) 0
Sales Per Share 21.31
EBITDA (p.s.) 2.16
Qtrly Earnings Growth 902.5 %
Operating Cash Flow 75 (M)
Levered Free Cash Flow 79 (M)
Stock Valuations
PE Ratio 174.81
PEG Ratio -4.1
Price to Book value 2.36
Price to Sales 2.62
Price to Cash Flow 40.29
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android